Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 5 15 SULFITE FREE W ELECT IN DEXTROSE 15 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 5 15 SULFITE FREE W ELECT IN DEXTROSE 15 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 5/15 is a parenteral nutrition solution that provides essential amino acids, electrolytes, and dextrose for intravenous use. Amino acids serve as building blocks for protein synthesis, dextrose provides calories for energy metabolism, and electrolytes maintain fluid and electrolyte balance. Calcium is essential for bone mineralization, neuromuscular function, and enzyme activation.
TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.
Intravenous infusion. Typical adult dose: 1.5–2.0 L/day of CLINIMIX E 5/15 (providing 75–100 g amino acids and 225–300 g dextrose per day) administered via central line; rate determined by glucose tolerance and fluid status.
Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.
None Documented
None Documented
Components have variable half-lives: amino acids ~0.5-1 h; dextrose ~2-4 h; electrolytes depend on renal function. Terminal half-life not applicable as a mixture.
Not applicable as TRAVASOL 4.25% IN DEXTROSE 25% is a nutrient solution, not a drug with a defined elimination half-life.
Renal excretion of amino acids and electrolytes; dextrose is metabolized to CO2 and water, with minimal renal excretion. Biliary/fecal elimination is negligible (<2%).
The amino acids and dextrose are completely metabolized; no significant renal or biliary excretion of intact product.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution